Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD)
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Hematology"
DOI: 10.1007/s12185-017-2222-4
Abstract: Three patients under hemodialysis (HD) with relapsed/refractory multiple myeloma (MM) were administered panobinostat/bortezomib/dexamethasone (FVD). Case 1: The patient was a 66-year-old male with BJP-κ. FVD was effective, but HD could not be discontinued. He developed… read more here.
Keywords: relapsed refractory; refractory multiple; bortezomib dexamethasone; panobinostat bortezomib ... See more keywords
Abstract 3014: Gene signatures identify quinolate phosphoribosyltransferase as a key mediator of acquired resistance to Panobinostat and Bortezomib in glioma, and NAD+ biosynthesis as a targetable pathway to reverse treatment resistance
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-3014
Abstract: Resistance of tumor cells to the induction of apoptosis is an important reason for the failure of anticancer treatments in patients with gliomas. Several factors working in concert have been implicated as sources of this… read more here.
Keywords: glioma; treatment; resistance; panobinostat bortezomib ... See more keywords